Brainstorm Cell Therapeutics 将来の成長
Future 基準チェック /06
Brainstorm Cell Therapeuticsは、15.9%と91.5%でそれぞれ年率15.9%で利益と収益が成長すると予測される一方、EPSはgrowで26.4%年率。
主要情報
15.9%
収益成長率
26.4%
EPS成長率
| Biotechs 収益成長 | 28.5% |
| 収益成長率 | 91.5% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 12 Nov 2024 |
今後の成長に関する最新情報
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
May 30Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02BrainStorm Cell Therapeutics EPS beats by $0.07
Apr 26Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
BrainStorm Cell Therapeutics EPS misses by $0.18
Feb 04Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17BrainStorm completes dosing in Phase 2 MS Study
Dec 18BrainStorm launches NurOwn Expanded Access Program
Dec 14What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13BrainStorm's NurOwn flunks in late-stage ALS study
Nov 17業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -26 | -44 | N/A | 3 |
| 12/31/2025 | N/A | -25 | -13 | -12 | 3 |
| 12/31/2024 | N/A | -14 | -14 | -14 | 3 |
| 9/30/2024 | N/A | -14 | -11 | -11 | N/A |
| 6/30/2024 | N/A | -13 | -14 | -14 | N/A |
| 3/31/2024 | N/A | -16 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -17 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -17 | -22 | -22 | N/A |
| 6/30/2023 | N/A | -22 | -20 | -20 | N/A |
| 3/31/2023 | N/A | -24 | -20 | -20 | N/A |
| 12/31/2022 | N/A | -24 | -19 | -19 | N/A |
| 9/30/2022 | N/A | -25 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -24 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -23 | -21 | -21 | N/A |
| 12/31/2021 | N/A | -24 | -27 | -26 | N/A |
| 9/30/2021 | N/A | -30 | -29 | -28 | N/A |
| 6/30/2021 | N/A | -29 | -29 | -29 | N/A |
| 3/31/2021 | N/A | -30 | -30 | -29 | N/A |
| 12/31/2020 | N/A | -32 | -36 | -35 | N/A |
| 9/30/2020 | N/A | -28 | -31 | -31 | N/A |
| 6/30/2020 | N/A | -29 | -28 | -28 | N/A |
| 3/31/2020 | N/A | -26 | -26 | -25 | N/A |
| 12/31/2019 | N/A | -23 | -12 | -11 | N/A |
| 9/30/2019 | N/A | -21 | -12 | -12 | N/A |
| 6/30/2019 | N/A | -18 | -15 | -15 | N/A |
| 3/31/2019 | N/A | -17 | -11 | -11 | N/A |
| 12/31/2018 | N/A | -14 | -13 | -12 | N/A |
| 9/30/2018 | N/A | -8 | -12 | -12 | N/A |
| 6/30/2018 | N/A | -8 | N/A | -1 | N/A |
| 3/31/2018 | N/A | -5 | N/A | -3 | N/A |
| 12/31/2017 | N/A | -5 | N/A | -2 | N/A |
| 9/30/2017 | N/A | -6 | N/A | -1 | N/A |
| 6/30/2017 | N/A | -5 | N/A | -5 | N/A |
| 3/31/2017 | N/A | -5 | N/A | -5 | N/A |
| 12/31/2016 | N/A | -5 | N/A | -6 | N/A |
| 9/30/2016 | N/A | -6 | N/A | -6 | N/A |
| 6/30/2016 | N/A | -7 | N/A | -8 | N/A |
| 3/31/2016 | N/A | -8 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -8 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -8 | N/A |
| 6/30/2015 | N/A | -10 | N/A | -7 | N/A |
| 3/31/2015 | N/A | -9 | N/A | -6 | N/A |
| 12/31/2014 | N/A | -9 | N/A | -4 | N/A |
| 9/30/2014 | N/A | -8 | N/A | -4 | N/A |
| 6/30/2014 | N/A | -6 | N/A | -4 | N/A |
| 3/31/2014 | N/A | -6 | N/A | -4 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: BCLI今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BCLI今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: BCLI今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BCLI来年は収益がないと予測されています。
高い収益成長: BCLI来年は収益がないと予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: BCLIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です